Jama Oncology最新文献

筛选
英文 中文
Relapse Patterns in Early-Stage Endometrial Cancer Based on Molecular Classification. 基于分子分类的早期子宫内膜癌复发模式
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-01 DOI: 10.1001/jamaoncol.2024.3239
Giorgio Bogani, Francesco Raspagliesi
{"title":"Relapse Patterns in Early-Stage Endometrial Cancer Based on Molecular Classification.","authors":"Giorgio Bogani, Francesco Raspagliesi","doi":"10.1001/jamaoncol.2024.3239","DOIUrl":"10.1001/jamaoncol.2024.3239","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1439-1440"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Anal Lesion in a 27-Year-Old Patient. 一名 27 岁患者的肛门病变
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-01 DOI: 10.1001/jamaoncol.2024.3411
Jérémy Baude, Hugues Mura, Alexis Lépinoy
{"title":"An Anal Lesion in a 27-Year-Old Patient.","authors":"Jérémy Baude, Hugues Mura, Alexis Lépinoy","doi":"10.1001/jamaoncol.2024.3411","DOIUrl":"10.1001/jamaoncol.2024.3411","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1437-1438"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cold Capping-A Medical Student's Perspective As a Caregiver. 冷敷--医学生作为护理人员的视角。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-01 DOI: 10.1001/jamaoncol.2024.2637
Fiona Evans
{"title":"Cold Capping-A Medical Student's Perspective As a Caregiver.","authors":"Fiona Evans","doi":"10.1001/jamaoncol.2024.2637","DOIUrl":"10.1001/jamaoncol.2024.2637","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1315-1316"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141903307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inclusion of American Indian, Alaska Native, Native Hawaiian, and Pacific Islander Patients in Clinical Trial Travel Time-Reply. 将美国印第安人、阿拉斯加原住民、夏威夷原住民和太平洋岛民患者纳入临床试验旅行时间--回复。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-01 DOI: 10.1001/jamaoncol.2024.3408
Hassal Lee, Neal A Palafox, Tobias Janowitz
{"title":"Inclusion of American Indian, Alaska Native, Native Hawaiian, and Pacific Islander Patients in Clinical Trial Travel Time-Reply.","authors":"Hassal Lee, Neal A Palafox, Tobias Janowitz","doi":"10.1001/jamaoncol.2024.3408","DOIUrl":"10.1001/jamaoncol.2024.3408","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1441-1442"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suicide Attempt and Suicide Death Among Spouses of Patients With Cancer. 癌症患者配偶中的自杀未遂和自杀死亡。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-01 DOI: 10.1001/jamaoncol.2024.3036
Qianwei Liu, Fen Yang, Krisztina D László, Kejia Hu, Maria Feychting, Dang Wei, Katja Fall, Unnur Valdimarsdóttir, Jiong Li, Fang Fang
{"title":"Suicide Attempt and Suicide Death Among Spouses of Patients With Cancer.","authors":"Qianwei Liu, Fen Yang, Krisztina D László, Kejia Hu, Maria Feychting, Dang Wei, Katja Fall, Unnur Valdimarsdóttir, Jiong Li, Fang Fang","doi":"10.1001/jamaoncol.2024.3036","DOIUrl":"10.1001/jamaoncol.2024.3036","url":null,"abstract":"<p><strong>Importance: </strong>Little is known about the risk of suicidal behavior in relation to having a spouse with a cancer diagnosis.</p><p><strong>Objective: </strong>To estimate the risk of suicide attempt and suicide death among spouses of patients with cancer.</p><p><strong>Design, setting, and participants: </strong>This nationwide cohort study in Denmark collected registry-based data from 1986 through 2016. Analyses were performed from August 8, 2022, to October 30, 2023. Individuals who had a spouse with a cancer diagnosed during 1986 to 2015 were compared with individuals whose spouse did not have a cancer diagnosis during the same period, randomly selected from the general population and matched by birth year and sex.</p><p><strong>Exposure: </strong>Having a spouse with a cancer diagnosis.</p><p><strong>Main outcomes and measures: </strong>Suicide attempt was identified through the Danish National Patient Register and the Danish Psychiatric Central Research Register, whereas suicide death was identified through the Danish Causes of Death Register, through 2016. Flexible parametric and Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs for suicide attempt and suicide death among spouses of patients with a cancer diagnosis.</p><p><strong>Results: </strong>The study included 409 338 exposed individuals and 2 046 682 unexposed individuals (median [IQR] age at cohort entry for both groups, 63 [54-70] years; 55.4% women). During the follow-up, 2714 incident cases of suicide attempt among exposed individuals (incidence rate [IR], 62.6 per 100 000 person-years) and 9994 among unexposed individuals (IR, 50.5 per 100 000 person-years) were identified, as well as 711 cases of suicide death among the exposed individuals (IR, 16.3 per 100 000 person-years) and 2270 among the unexposed individuals (IR, 11.4 per 100 000 person-years). An increased risk of suicide attempt (HR, 1.28; 95% CI, 1.23-1.34) and suicide death (HR, 1.47; 95% CI, 1.35-1.60) was observed among spouses of patients with cancer throughout the follow-up. The increased risk was particularly notable during the first year after the cancer diagnosis, with an HR of 1.45 (95% CI, 1.27-1.66) for suicide attempt and 2.56 (95% CI, 2.03-3.22) for suicide death. There was a greater risk increase for both suicide attempt and suicide death when the cancer was diagnosed at an advanced stage or when the spouse died after the cancer diagnosis.</p><p><strong>Conclusions and relevance: </strong>These findings suggest a need for clinical and societal awareness to prevent suicidal behaviors among spouses of patients with cancer, particularly during the first year following the cancer diagnosis.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1323-1330"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inclusion of American Indian, Alaska Native, Native Hawaiian, and Pacific Islander Patients in Clinical Trial Travel Time. 将美国印第安人、阿拉斯加原住民、夏威夷原住民和太平洋岛民患者纳入临床试验的旅行时间。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-01 DOI: 10.1001/jamaoncol.2024.3405
Megan Y Gimmen, Alec J Calac, Kekoa Taparra
{"title":"Inclusion of American Indian, Alaska Native, Native Hawaiian, and Pacific Islander Patients in Clinical Trial Travel Time.","authors":"Megan Y Gimmen, Alec J Calac, Kekoa Taparra","doi":"10.1001/jamaoncol.2024.3405","DOIUrl":"10.1001/jamaoncol.2024.3405","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1440-1441"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis. 免疫检查点抑制剂诱发的心脏毒性:系统回顾与元分析》。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-01 DOI: 10.1001/jamaoncol.2024.3065
Dorte Lisbet Nielsen, Carsten Bogh Juhl, Ole Haagen Nielsen, Inna Markovna Chen, Joerg Herrmann
{"title":"Immune Checkpoint Inhibitor-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.","authors":"Dorte Lisbet Nielsen, Carsten Bogh Juhl, Ole Haagen Nielsen, Inna Markovna Chen, Joerg Herrmann","doi":"10.1001/jamaoncol.2024.3065","DOIUrl":"10.1001/jamaoncol.2024.3065","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Immune checkpoint inhibitors (ICIs) improve outcomes in a wide range of cancers; however, serious adverse effects, including cardiovascular adverse effects (CVAEs), can occur.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To determine the incidence of CVAEs and analyze data on the management of myocarditis in patients exposed to ICIs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data sources: &lt;/strong&gt;PubMed, Embase, and Cochrane Central Register of Controlled Trials from inception were searched on April 4, 2023.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Study selection: &lt;/strong&gt;Two separate studies were performed. Key inclusion criteria for study 1 were phases 1 to 4 trials involving adults with malignant neoplasms treated with an ICI and toxicity data; for study 2, publications (case reports and retrospective analyses) on clinical manifestations and treatment of patients with ICI-induced CVAEs. Studies with dose escalation or fewer than 11 patients in each group and all case reports, retrospective analyses, letters, reviews, and editorials were excluded from study 1. Studies not published in English were excluded from study 2.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Data extraction and synthesis: &lt;/strong&gt;The PRISMA guidelines and Cochrane Handbook for Systematic Reviews were followed. Data were extracted independently by 2 researchers. A meta-analysis of the incidence of CVAEs in clinical trials and a systematic review of the evidence for the management of myocarditis were performed. Data were pooled using a random-effects model.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;In study 1, the primary outcome was incidence CVAEs in clinical trials with ICIs and ICI combination therapies. Study 2 examined evidence supporting specific management strategies that may decrease the mortality rate of myocarditis. The primary outcomes were planned before data collection began.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In study 1, a total of 83 315 unique participants in 589 unique trials were included in the meta-analysis. Incidence of CVAEs induced by anti-programmed cell death 1 and/or programmed cell death ligand 1 was 0.80% (95% CI, 0%-1.66%) in clinical trials, with no differences between the compounds, except for cemiplimab, which was associated with a higher risk of CVAEs. Incidence of CVAEs following ipilimumab treatment was 1.07% (95% CI, 0%-2.58%). The incidence of myocarditis was significantly higher following treatment with dual ICIs. However, CVAE incidence was not higher with dual ICIs, ICI combination with chemotherapy, or tyrosine kinase inhibitors. Evidence from randomized clinical trials on recommended monitoring and treatment strategies for ICI-induced myocarditis was lacking. Study 2 showed that myocarditis-associated mortality occurred in 83 of 220 patients (37.7%). Prospective data from 40 patients with myocarditis indicated that systematic screening for respiratory muscle involvement, coupled with active ventilation, prompt use of abatacept, and the addition of ruxolitinib, may decrease the mortalit","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1390-1399"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11342217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142019242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aspirin Use and Incidence of Colorectal Cancer According to Lifestyle Risk. 根据生活方式风险划分的阿司匹林使用情况和结直肠癌发病率。
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-01 DOI: 10.1001/jamaoncol.2024.2503
Daniel R Sikavi, Kai Wang, Wenjie Ma, David A Drew, Shuji Ogino, Edward L Giovannucci, Yin Cao, Mingyang Song, Long H Nguyen, Andrew T Chan
{"title":"Aspirin Use and Incidence of Colorectal Cancer According to Lifestyle Risk.","authors":"Daniel R Sikavi, Kai Wang, Wenjie Ma, David A Drew, Shuji Ogino, Edward L Giovannucci, Yin Cao, Mingyang Song, Long H Nguyen, Andrew T Chan","doi":"10.1001/jamaoncol.2024.2503","DOIUrl":"10.1001/jamaoncol.2024.2503","url":null,"abstract":"<p><strong>Importance: </strong>Aspirin reduces the risk of colorectal cancer (CRC). Identifying individuals more likely to benefit from regular aspirin use for CRC prevention is a high priority.</p><p><strong>Objective: </strong>To assess whether aspirin use is associated with the risk of CRC across different lifestyle risk factors.</p><p><strong>Design, setting, and participants: </strong>A prospective cohort study among women in the Nurses' Health Study (1980-2018) and men in the Health Professionals Follow-Up Study (1986-2018) was conducted. Data analysis was performed from October 1, 2021, to May 22, 2023.</p><p><strong>Exposures: </strong>A healthy lifestyle score was calculated based on body mass index, alcohol intake, physical activity, diet, and smoking with scores ranging from 0 to 5 (higher values corresponding to a healthier lifestyle). Regular aspirin use was defined as 2 or more standard tablets (325 mg) per week.</p><p><strong>Main outcome and measures: </strong>Outcomes included multivariable-adjusted 10-year cumulative incidence of CRC, absolute risk reduction (ARR), and number needed to treat associated with regular aspirin use by lifestyle score and multivariable-adjusted hazard ratios for incident CRC across lifestyle scores.</p><p><strong>Results: </strong>The mean (SD) baseline age of the 107 655 study participants (63 957 women from the Nurses' Health Study and 43 698 men from the Health Professionals Follow-Up Study) was 49.4 (9.0) years. During 3 038 215 person-years of follow-up, 2544 incident cases of CRC were documented. The 10-year cumulative CRC incidence was 1.98% (95% CI, 1.44%-2.51%) among participants who regularly used aspirin compared with 2.95% (95% CI, 2.31%-3.58%) among those who did not use aspirin, corresponding to an ARR of 0.97%. The ARR associated with aspirin use was greatest among those with the unhealthiest lifestyle scores and progressively decreased with healthier lifestyle scores (P < .001 for additive interaction). The 10-year ARR for lifestyle scores 0 to 1 (unhealthiest) was 1.28%. In contrast, the 10-year ARR for lifestyle scores 4 to 5 (healthiest) was 0.11%. The 10-year number needed to treat with aspirin was 78 for participants with lifestyle scores 0 to 1, 164 for score 2, 154 for score 3, and 909 for scores 4 to 5. Among the components of the healthy lifestyle score, the greatest differences in ARR associated with aspirin use were observed for body mass index and smoking.</p><p><strong>Conclusions and relevance: </strong>In this cohort study, aspirin use was associated with a greater absolute reduction in risk of CRC among individuals with less healthy lifestyles. The findings of the study suggest that lifestyle risk factors may be useful to identify individuals who may have a more favorable risk-benefit profile for cancer prevention with aspirin.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1354-1361"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11295063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRI-Linac-Based Radiotherapy-Promising or Hype? 基于 MRI-Linac 的放射治疗--前景广阔还是虚有其表?
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-01 DOI: 10.1001/jamaoncol.2024.2488
Mack Roach, Stella Ling, Pamela W Coleman
{"title":"MRI-Linac-Based Radiotherapy-Promising or Hype?","authors":"Mack Roach, Stella Ling, Pamela W Coleman","doi":"10.1001/jamaoncol.2024.2488","DOIUrl":"10.1001/jamaoncol.2024.2488","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1313-1314"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers. 通过机器学习分类器预测化放疗期间的意外住院情况
IF 28.4 1区 医学
Jama Oncology Pub Date : 2024-10-01 DOI: 10.1001/jamaoncol.2024.3620
Xue Bai, Xia Cui, Wenquan Niu
{"title":"Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers.","authors":"Xue Bai, Xia Cui, Wenquan Niu","doi":"10.1001/jamaoncol.2024.3620","DOIUrl":"10.1001/jamaoncol.2024.3620","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1442"},"PeriodicalIF":28.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信